The traditional symptoms of liver cancer, such as a swollen abdomen or an enlarged liver, have many subtle signs that can easily be missed. Never ignore these signs, because early detection can get timely treatment."Reader's Dige..
August 19, 2018: Singapore biotechnology company Lion TCR Pte. Ltd. was approved by the Singapore Health Sciences Authority (HSA), and its candidate product (LioCyx ™) can be used for phase I / II clinical research for the treat..
Hepatitis C is primarily to blame for liver cancer, one of the deadliest cancers. In addition, complications of fatty liver disease are also a cause of liver cancer. At present, researchers are trying to treat liver cancer by imp..
Research reports published in the Journal of Cancer Epidemiology, Biomarkers, and Prevention show that there is a negative correlation between circulating 25-hydroxyvitamin D [25 (OH) D] levels and liver cancer risk and chron..
Nonalcoholic fatty liver disease (NAFLD) is a very common disease. To better understand the link between NAFLD and hepatocellular carcinoma (HCC) risk, researchers at Baylor College of Medicine conducted a large Retrospective stud..
Researchers at the Mayo Clinic in the United States reported at the 2018 Digestive Disease Week meeting that they have developed a DNA blood test that can correctly identify 95% of common liver cancer cases.At present, ultrasound ..
Based on data from the REFLECT phase III trial, the US Food and Drug Administration (FDA) approved Lenvima as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). The test was published in The ..
A research team at the Cancer Research Institute (CSI) of the National University of Singapore has developed a novel peptide drug called FFW that may prevent the development of hepatocellular carcinoma (HCC) or primary liver ca..
The Swiss Roche Group announced yesterday that TECENTRIQ® (atezolizumab) in combination with Avastin® (bevacizumab) has been approved by the US Food and Drug Administration (FDA) for breakthrough therapy for initial (first-line)..
According to a study published in the New England Journal of Medicine published on July 5, Cabozantinib's overall and progression-free survival in patients with advanced hepatocellular carcinoma was significantly better than the p..